Basic Information
| LncRNA/CircRNA Name | LOC134466 |
| Synonyms | ZNF300P1 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | 5-Aza | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, etc. |
| Sample | endometrial tissue, endometrial cancer, KLE, Ishikawa, HEC1A, and the normal endometrial cell line hEEC |
| Expression Pattern | down-regulated |
| Function Description | EC progression was promoted by hypermethylated LOC134466 and TAC1. Moreover, TAC1 transcription was regulated by LOC134466 via hsa-miR-196a-5p binding. LOC134466 and TAC1 demethylation by 5-Aza-2-Deoxycytidine inhibited EC cells proliferation and accelerated cell apoptosis. Furthermore, the expression of TACR1, TACR2 and TACR3 was remarkably decreased through LOC134466 and TAC1 treatments. Our findings establish a novel regulatory axis, LOC134466/hsa-miR-196a-5p/TAC1. Downregulation of the axis promoted EC development through TACR3, which further activated neuroactive ligand-receptor interaction. |
| Pubmed ID | 30485833 |
| Year | 2018 |
| Title | LOC134466 methylation promotes oncogenesis of endometrial carcinoma through LOC134466/hsa-miR-196a-5p/TAC1 axis |
External Links
| Links for LOC134466 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |